EPAS1 and neoplasm: Since ccRCC is considered a “metabolic disease” and “VHL hyper-mutation disease”, one unexplored avenue of controlling this tumor is to target the HIF2α/LINC02609/APOL1 pathway, which may offer a veritable therapeutic window.